Akebia Therapeutics, Inc. (AKBA) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
AKBA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AKBA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 83.3% | 9.9% | -2.3% |
| 2024 | 60.6% | -31.5% | -43.3% |
| 2023 | 61.9% | -23.8% | -26.7% |
| 2022 | 92.3% | -27.6% | -32.2% |
| 2021 | 61.5% | -125.0% | -133.3% |
Download Data
Export AKBA earnings history in CSV or JSON format
Free sign-in required to download data
Akebia Therapeutics, Inc. (AKBA) Earnings Overview
As of May 8, 2026, Akebia Therapeutics, Inc. (AKBA) reported trailing twelve-month net income of -$21M, reflecting +93.7% year-over-year growth. The company earned $-0.08 per diluted share over the past four quarters, with a net profit margin of -2.3%.
Looking at the long-term picture, AKBA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2025, representing a new all-time high.
Akebia Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FOLD (-$27M net income, -4.3% margin), PTGX (-$115M net income, -282.8% margin), CYCN (-$4M net income, -170.1% margin), AKBA has outperformed on profitability metrics. Compare AKBA vs FOLD →
AKBA Earnings vs Peers
Earnings metrics vs comparable public companies
AKBA Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$5M | +92.3% | $23M | $-0.02 | -2.3% | 9.9% |
| 2024 | -$69M | -33.7% | -$50M | $-0.33 | -43.3% | -31.5% |
| 2023 | -$52M | +44.9% | -$46M | $-0.28 | -26.7% | -23.8% |
| 2022 | -$94M | +66.6% | -$81M | $-0.58 | -32.2% | -27.6% |
| 2021 | -$282M | +26.7% | -$265M | $-1.48 | -133.3% | -125.0% |
| 2020 | -$385M | -37.6% | -$378M | $-2.53 | -130.6% | -128.2% |
| 2019 | -$280M | -62.7% | -$286M | $-2.36 | -83.5% | -85.5% |
| 2018 | -$172M | -123.5% | -$178M | $-1.47 | -82.7% | -85.8% |
| 2017 | -$77M | +43.3% | -$80M | $-1.77 | -43.2% | -44.9% |
| 2016 | -$136M | -123.6% | -$136M | $-3.60 | -8843.5% | -8889.9% |
See AKBA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKBA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AKBA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAKBA — Frequently Asked Questions
Quick answers to the most common questions about buying AKBA stock.
Is AKBA growing earnings?
AKBA EPS is $-0.08, with earnings growth accelerating to +93.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-21M.
What are AKBA's profit margins?
Akebia Therapeutics, Inc. net margin is -2.3%, with operating margin at +9.9%. Below-average margins reflect competitive or cost pressures.
How consistent are AKBA's earnings?
AKBA earnings data spans 2012-2025. The accelerating earnings trend is +93.7% YoY. Historical data enables comparison across business cycles.